Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50 participants
OBSERVATIONAL
2014-10-23
2017-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Recent neuroimaging data show that brain processing of social exclusion activate brain regions that are central to the pathophysiology of MDD. Some of these regions are also known to be activated during physical pain and may contribute to the aversive dimension of the experienced rejection. Pro-inflammatory cytokines are involved in MDD physiopathology and can induce social withdrawal behavior. Inflammation can modulate social interactions in mammals. Moreover, after a social stress such as social rejection, blood cytokines increase. At a cognitive level, self-esteem can modulate the sensitivity to social rejection.
The major objective of the trial is to study sensitivity to social signals in MDD patient compared to healthy subject.
The investigators hypothesize in MDD patient : (1) decrease of rapid facial reactions (RFR) to dynamic emotional faces expressing joy, (2) increase of RFR to dynamic emotional faces expressing sadness, (3) decrease of prosocial reaction after experimental social rejection.
Secondary objective is to identify psychological and biological mediators We hypothetize in MDD patient: (1)mediating effect of systemic inflammatory cytokines, an (2) mediating effect of state self esteem 30 MDD patients and 60 healthy subject will be included. They will encounter psychiatric and psychometric evaluation. Their facial EMG will be recorded to assess RFR to dynamic emotional faces created by photo morphing from KDEF emotional faces database, coupled to occulometric recording. Subjects will perform cyberball game as an experimental inclusion or exclusion task and the trustgame task as an implicit evaluation of their prosocial behavior. Questionnaires will assess explicit measurement of social rejection pain and desire of affiliation. Inflammatory markers will be measured in a blood sample before the cyberball task for every subjects and 6 hours later for 20 healthy volunteers. Dosage of IL-6, IL-10, TNFa, IP-10, MCP-1, MIP-1b, Rantes, sIL-6Ra, IL1ra, VEGF, Leptin, PECAM1, sTie2, sVEGFR1, sVEGFR2 will be performed by luminex technique and usCRP, srIL2 ans sCD14 by ELISA technique.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neuronal Responses to Social Feedback in Major Depressive Disorder
NCT02180607
Relevance of a Telemedicine Monitoring in the Management of Depression
NCT06076317
Role of Self-focused Attention in Depression
NCT05464550
Impairment of the Cognitive Flow in the Development of a Depressive Disorder and Suicidal Ideas
NCT03674580
Cognitive Markers of Response to Treatment in Resistant Depression
NCT02774980
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MDD patients
emotional facial stimuli cyberball game
emotional facial stimuli
Subjects watch passively dynamic facial emotions obtained by emotionnal faces photos morphing. Their rapid facial reactions are recorded by faciel EMG device as eye movement by occulometric device.
Cyberball game
Ball tossing computer game to manipulate social inclusion status : rejection or inclusion. Social behavior, social pain and inflammatory modification will be assessed after the game.
healthy subjects
emotional facial stimuli cyberball game
emotional facial stimuli
Subjects watch passively dynamic facial emotions obtained by emotionnal faces photos morphing. Their rapid facial reactions are recorded by faciel EMG device as eye movement by occulometric device.
Cyberball game
Ball tossing computer game to manipulate social inclusion status : rejection or inclusion. Social behavior, social pain and inflammatory modification will be assessed after the game.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
emotional facial stimuli
Subjects watch passively dynamic facial emotions obtained by emotionnal faces photos morphing. Their rapid facial reactions are recorded by faciel EMG device as eye movement by occulometric device.
Cyberball game
Ball tossing computer game to manipulate social inclusion status : rejection or inclusion. Social behavior, social pain and inflammatory modification will be assessed after the game.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* benefit social health insurance
* french speaker and reader
* can stop smoking one day
* volunteer to participate
For 1st group :
* actual MDD diagnosed by a psychiatrist and meet the DSM IV criterias of MDD
* no antidepressant treatment or antidepressant treatment for less than 7 days.
Exclusion Criteria
* weekly sport \> 3 hours
* pregnancy
* fever or other infection symptoms during the last month
* significant or unstable disease, especially neurologic or inflammatory.
* recent history of coronary disease, ulcer, COPD, severe dyslipemia, kidney or liver failure.
* severe smoking addiction (fagerström \> 8)
* antiinflammatory or immunomodulatory treatment during last month
For 1st group :
* no psychiatric treatment except benzodiazepin if no severe vigilance trouble and antidepressant treatment more than 7 days
* subjects under legal protection
* constraint hospitalization
* significant suicidal risk
* resistant MDD
* psychiatric comorbidity
For 2nd group :
\- psychiatric disease, actual or past according to DSM IV criterias
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut National de la Santé Et de la Recherche Médicale, France
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ICM, Pitié Salpêtrière Hospital
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013-A01484-41
Identifier Type: REGISTRY
Identifier Source: secondary_id
C13-31
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.